Equities

Advanced Medical Solutions Group PLC

Advanced Medical Solutions Group PLC

Actions
  • Price (EUR)2.90
  • Today's Change-0.10 / -3.33%
  • Shares traded7.50k
  • 1 Year change+40.78%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Advanced Medical Solutions Group PLC's net income deteriorated -22.14% from 20.41m to 15.89m despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
Gross margin54.45%
Net profit margin8.49%
Operating margin9.47%
Return on assets3.38%
Return on equity4.59%
Return on investment3.64%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Advanced Medical Solutions Group PLC fell by 22.10m. However, the company earned 12.35m from its operations for a Cash Flow Margin of 9.78%. In addition the company used 20.27m on investing activities and also paid 13.62m in financing cash flows.
Cash flow per share0.103
Price/Cash flow per share24.57
Book value per share1.12
Tangible book value per share0.5031
More ▼

Balance sheet in GBPView more

Advanced Medical Solutions Group PLC appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio8.39
Quick ratio6.80
Total debt/total equity0.3701
Total debt/total capital0.2702
More ▼

Growth rates in GBP

SmartText is unavailable
Div yield(5 year avg)0.75%
Div growth rate (5 year)12.32%
Payout ratio (TTM)32.41%
EPS growth(5 years)-6.99
EPS (TTM) vs
TTM 1 year ago
-42.92
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.